Evidence map›Paper›PMID 30957097›Full record

ArticleCPQ neurology and psychology2018

Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated).

Blum Kenneth, Modestino J Edward, Gondre Lewis C Marjorie, Baron David, Steinberg Bruce, Thanos K Panayotis, Downs B William, Siwicki Davis, Lott Lisa, Braverman R Eric and 4 more

Open access · greenAbstract readBibliography
In one paragraph

Article in CPQ neurology and psychology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Are We Getting High Cause the Thrill is Gone?Journal of addiction psychiatry · 2023
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 4 countries.

Blum KennethWestern University Health Sciences, Graduate School of Biomedical Sciences, Pomona, CA.
Modestino J EdwardDivision of Precision Addiction Management, Geneus Health, LLC., San Antonio, TX, USA.
Gondre Lewis C MarjorieDivision of Precision Addiction Management, Geneus Health, LLC., San Antonio, TX, USA.
Baron DavidWestern University Health Sciences, Graduate School of Biomedical Sciences, Pomona, CA.
Steinberg BruceDivision of Precision Addiction Management, Geneus Health, LLC., San Antonio, TX, USA.
Thanos K PanayotisDivision of Precision Addiction Management, Geneus Health, LLC., San Antonio, TX, USA.
Downs B WilliamDivision of Nutrigenomics, Victory Nutrition International. LLC., Lederach, PA.
Siwicki DavisDominion Diagnostics, LLC., North Kingston, RI, USA.
Lott LisaDivision of Precision Addiction Management, Geneus Health, LLC., San Antonio, TX, USA.
Braverman R EricDepartment of Clinical Neurology, Path Foundation NY, New York, USA.
Moran MarkDivision of Precision Addiction Management, Geneus Health, LLC., San Antonio, TX, USA.
Miller DavidDivision of Addiction Therapy Research, Nupathways, Inc., Meadow Ridge Dr. Innsbrook, MO, USA.
Fried LyleDivision of Precision Addiction Management, Geneus Health, LLC., San Antonio, TX, USA.
Badgaiyan D RajendraDivision of Precision Addiction Management, Geneus Health, LLC., San Antonio, TX, USA.
Christus Health · USEötvös Loránd University · HUHoward University · USMount Sinai Hospital · USNational Drug Addiction Center · BGVictim Support · GB

Funding

Research_ProjectU54HD090257 · NICHD · CHILDREN'S RESEARCH INSTITUTE · PI JAISWAL, JYOTI K · 2016 to 2020
$5.9M
Anandamide Transport InhibitorsR01DA035923 · NIDA · STATE UNIVERSITY NEW YORK STONY BROOK · PI KACZOCHA, MARTIN · 2013 to 2017
$3.8M
FABPs: Novel Roles in Pain and InflammationR01DA035949 · NIDA · STATE UNIVERSITY NEW YORK STONY BROOK · PI KACZOCHA, MARTIN · 2014 to 2022
$3.0M
Excessive Alcohol Drinking Associated with GABA Alpha 2-Regulated TLR4 ExpressionR01AA021262 · NIAAA · HOWARD UNIVERSITY · PI AURELIAN, LAURE, GONDRE-LEWIS, MARJORIE C · 2013 to 2017
$2.3M
Dopamine Neurotransmission in Tourette SyndromeR01NS073884 · NINDS · UNIVERSITY OF MINNESOTA · PI BADGAIYAN, RAJENDRA D · 2012 to 2016
$2.2M
Skeletal Effects of MethylphenidateR01HD070888 · NICHD · STATE UNIVERSITY NEW YORK STONY BROOK · PI KOMATSU, DAVID E · 2013 to 2017
$1.6M
Detection of Dopamine Release During a Cognitive TaskR21MH073624 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI BADGAIYAN, RAJENDRA D · 2005 to 2006
$368k
A Systematic Medical Approach to Reward Transformation (SMART) for Brain Health in Opioid Use DisorderR41MD012318 · NIMHD · VERSA INTEGRATED SOLUTIONS, INC. · PI BLUM, KENNETH, GONDRE-LEWIS, MARJORIE C · 2017 to 2017
$221k
Dopamine Neurotransmission in AddictionI01CX000479 · VA · VA WESTERN NEW YORK HEALTHCARE SYSTEM · PI BADGAIYAN, RAJENDRA D · 2013 to 2014
–
CSRD VA I01 CX000479NIAAA NIH HHS R01 AA021262NICHD NIH HHS R01 HD070888NICHD NIH HHS U54 HD090257NIDA NIH HHS R01 DA035923NIDA NIH HHS R01 DA035949NIMHD NIH HHS R41 MD012318NIMH NIH HHS R21 MH073624NINDS NIH HHS R01 NS073884
6 · The paper itself

Abstract

backgroundWe are facing a significant challenge in combatting the current opioid and drug epidemic worldwide. In the USA, although there has been notable progress, in 2017 alone 72,000 people died from a narcotic overdose. The NIAAA & NIDA continue to struggle with innovation to curb or eliminate this unwanted epidemic. The current FDA list of approved Medication Assistance Treatments (MATS) work by primarily blocking dopamine function and release at the pre-neuron in the nucleus accumbens. We oppose this option in the long term tertiary treatment but agree for short term harm reduction potential. BIBLIOGRAPHY PRESENTATION: As an alternative motif, the utilization of a well-researched neuro-nutrient called KB220 has been intensely investigated in at least 38 studies showing evident effects related to everything from AMA rate, attenuation of craving behavior, reward system activation including BOLD dopamine signaling, relapse prevention, as well as reduction in stress, anger, and aggressive behaviors. We are continuing research especially as it relates to genetic risk, including the now patented Genetic Addiction Risk Score (GARS

conclusionBased on animal research and clinical trials as presented herein, the Pro-Dopamine Regulator known as KB220 shows promise in the addiction and pain space. Other neurobiological and genetic studies are required to help understand the mechanism of action of this neuro-nutrient. However, the evidence to date points to induction of "dopamine homeostasis"enabling an asymptotic approach for epigenetic induced "normalization" of brain neurotransmitter signaling and associated improved function in the face of either genetic or epigenetic impairment of the Brain Reward Cascade (BRC).With that said, we are encouraged about these results as published over the last 50 years and look forward to continued advancements related to appropriate nutrigenomic solutions to the millions of victims of all addictions (from drugs to food to smoking to gambling and gaming especially in our next generation) called Reward Surfeit Syndrome (RSS) in adolescents and Reward Deficiency Syndrome (RDS) in adulthood.

Indexed as

AnnotatedGenetic Addiction Risk Score (GARS®)Kb220Precision Addiction Management (PAM®)Restoregen Variant

Identifiers

PMID30957097
PMCPMC6448775
OpenAlexW2984836846

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.